Angela Mah

Angela Mah

Auto-generated profile, based on publicly available information

Angela Mah

Stanford Program in Epithelial Biology, Stanford University, Stanford, California

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ASAnkit Srivastava
Ankit Srivastava
CTCristina Tommasi
Cristina Tommasi
DSDane Sessions
Dane Sessions
AMAngela Mah
Angela Mah
TBTomas Bencomo
Tomas Bencomo
CLCarolyn S. Lee
Carolyn S. Lee
Epithelial squamous cell carcinomas (SCC) most commonly originate in the skin, where they display disruptions in the normally tightly regulated homeostatic balance between keratinocyte proliferation and terminal differentiation. We performed a transcriptome-wide screen for genes of unknown function that possess inverse expression patterns in differentiating keratinocytes compared with cutaneous SCC (cSCC), leading to the identification of MAB21L4 (C2ORF54) as an enforcer of terminal differentiation that suppresses carcinogenesis. Loss of MAB21L4 in human cSCC organoids increased expression of RET to enable malignant progression. In addition to transcriptional upregulation of RET, deletion of MAB21L4 preempted recruitment of the CacyBP-Siah1 E3 ligase complex to RET and reduced its ubiquitylation. In SCC organoids and in vivo tumor models, genetic disruption of RET or selective inhibition of RET with BLU-667 (pralsetinib) suppressed SCC growth while inducing concomitant differentiation. Overall, loss of MAB21L4 early during SCC development blocks differentiation by increasing RET expression. These results suggest that targeting RET activation is a potential therapeutic strategy for treating SCC. Significance: Downregulation of RET mediated by MAB21L4–CacyBP interaction is required to induce epidermal differentiation and suppress carcinogenesis, suggesting RET inhibition as a potential therapeutic approach in squamous cell carcinoma.

31 March 2023
Verified
Other
Open access
ASAnkit Srivastava
Ankit Srivastava
CTCristina Tommasi
Cristina Tommasi
DSDane Sessions
Dane Sessions
AMAngela Mah
Angela Mah
TBTomas Bencomo
Tomas Bencomo
CLCarolyn S. Lee
Carolyn S. Lee
Supplementary Data from MAB21L4 Deficiency Drives Squamous Cell Carcinoma via Activation of RET

31 March 2023
Verified
Other
Open access
ASAnkit Srivastava
Ankit Srivastava
CTCristina Tommasi
Cristina Tommasi
DSDane Sessions
Dane Sessions
AMAngela Mah
Angela Mah
TBTomas Bencomo
Tomas Bencomo
CLCarolyn S. Lee
Carolyn S. Lee
Supplementary Data from MAB21L4 Deficiency Drives Squamous Cell Carcinoma via Activation of RET

31 March 2023
Verified
Other
Open access
ASAnkit Srivastava
Ankit Srivastava
CTCristina Tommasi
Cristina Tommasi
DSDane Sessions
Dane Sessions
AMAngela Mah
Angela Mah
TBTomas Bencomo
Tomas Bencomo
CLCarolyn S. Lee
Carolyn S. Lee
Epithelial squamous cell carcinomas (SCC) most commonly originate in the skin, where they display disruptions in the normally tightly regulated homeostatic balance between keratinocyte proliferation and terminal differentiation. We performed a transcriptome-wide screen for genes of unknown function that possess inverse expression patterns in differentiating keratinocytes compared with cutaneous SCC (cSCC), leading to the identification of MAB21L4 (C2ORF54) as an enforcer of terminal differentiation that suppresses carcinogenesis. Loss of MAB21L4 in human cSCC organoids increased expression of RET to enable malignant progression. In addition to transcriptional upregulation of RET, deletion of MAB21L4 preempted recruitment of the CacyBP-Siah1 E3 ligase complex to RET and reduced its ubiquitylation. In SCC organoids and in vivo tumor models, genetic disruption of RET or selective inhibition of RET with BLU-667 (pralsetinib) suppressed SCC growth while inducing concomitant differentiation. Overall, loss of MAB21L4 early during SCC development blocks differentiation by increasing RET expression. These results suggest that targeting RET activation is a potential therapeutic strategy for treating SCC.Significance:Downregulation of RET mediated by MAB21L4–CacyBP interaction is required to induce epidermal differentiation and suppress carcinogenesis, suggesting RET inhibition as a potential therapeutic approach in squamous cell carcinoma.

31 March 2023
Verified
Other
Open access
ASAnkit Srivastava
Ankit Srivastava
CTCristina Tommasi
Cristina Tommasi
DSDane Sessions
Dane Sessions
AMAngela Mah
Angela Mah
TBTomas Bencomo
Tomas Bencomo
CLCarolyn S. Lee
Carolyn S. Lee
Epithelial squamous cell carcinomas (SCC) most commonly originate in the skin, where they display disruptions in the normally tightly regulated homeostatic balance between keratinocyte proliferation and terminal differentiation. We performed a transcriptome-wide screen for genes of unknown function that possess inverse expression patterns in differentiating keratinocytes compared with cutaneous SCC (cSCC), leading to the identification of MAB21L4 (C2ORF54) as an enforcer of terminal differentiation that suppresses carcinogenesis. Loss of MAB21L4 in human cSCC organoids increased expression of RET to enable malignant progression. In addition to transcriptional upregulation of RET, deletion of MAB21L4 preempted recruitment of the CacyBP-Siah1 E3 ligase complex to RET and reduced its ubiquitylation. In SCC organoids and in vivo tumor models, genetic disruption of RET or selective inhibition of RET with BLU-667 (pralsetinib) suppressed SCC growth while inducing concomitant differentiation. Overall, loss of MAB21L4 early during SCC development blocks differentiation by increasing RET expression. These results suggest that targeting RET activation is a potential therapeutic strategy for treating SCC.Significance:Downregulation of RET mediated by MAB21L4–CacyBP interaction is required to induce epidermal differentiation and suppress carcinogenesis, suggesting RET inhibition as a potential therapeutic approach in squamous cell carcinoma.